Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Update

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was the target of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 21,300,000 shares, a drop of 21.4% from the January 15th total of 27,110,000 shares. Based on an average trading volume of 2,560,000 shares, the days-to-cover ratio is currently 8.3 days.

Institutional Trading of Lineage Cell Therapeutics

A number of institutional investors have recently bought and sold shares of LCTX. Fort Sheridan Advisors LLC increased its stake in Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after purchasing an additional 23,000 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in Lineage Cell Therapeutics in the fourth quarter valued at $29,000. HighTower Advisors LLC increased its stake in Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after purchasing an additional 19,100 shares during the last quarter. SG Americas Securities LLC increased its stake in Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after purchasing an additional 18,053 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Lineage Cell Therapeutics by 33.0% in the fourth quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock valued at $48,000 after purchasing an additional 23,527 shares during the last quarter. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on LCTX shares. Maxim Group decreased their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, January 10th. D. Boral Capital cut their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research report on Tuesday.

Lineage Cell Therapeutics Trading Up 6.9 %

LCTX opened at $0.69 on Friday. The firm has a market cap of $150.99 million, a price-to-earnings ratio of -5.71 and a beta of 1.21. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.